Výsledky vyhledávání - "Zenith Nelson"

Full-dose irinotecan plus platinum (IP) with concurrent thoracic radiotherapy (C-TRT) in unresectable locally advanced non-small cell lung cancer (LA-NSCLC)

Autor: Zenith Nelson, Raid Aljumaily, Wenimar D. Salvador, J. Zhang, Teresa Parent, D. Fried, Julian G. Rosenman, Susan Eubanks, Tithi Biswas, Mark R. Bowling, Suzanne Russo, Stephen Tiley, Paul R. Walker

Publikováno v: Journal of Clinical Oncology. 30:e17547-e17547

e17547 Background: Weekly paclitaxel-carboplatin or cisplatin-etoposide with C-TRT is the standard of care for unresectable LA-NSCLC, with median survival time (MST) of 16-24 months and 3 year overall survival (OS) of 17-27%. Irinotecan plus platinum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86747df524a053cd85d6da78cae34534
https://doi.org/10.1200/jco.2012.30.15_suppl.e17547

Zobrazit plný text záznamu

Surgical pathology findings of neoadjuvant full-dose irinotecan and cisplatin (IP) with concurrent thoracic radiation therapy (C-TRT) in stage III non-small cell lung cancer (NSCLC)

Autor: Teresa Parent, Raid Aljumaily, Mark R. Bowling, Suzanne Russo, Sharon Ben-Or, D. Fried, Paul R. Walker, Jon F. Moran, Zenith Nelson, Susan Eubanks, Julian G. Rosenman, Richard Fred Williams, Tithi Biswas

Publikováno v: Journal of Clinical Oncology. 30:e17550-e17550

e17550 Background: Neoadjuvant C-TRT in stage IIIA NSCLC has become a standard of care. C-TRT sterilizes N2 nodes far better than primary tumors. TRT dose does seem to make a difference. In Intergroup 0139 with 45 Gy pre-op TRT, ypT0N0 was 18% and yp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5916a5ce685adc81a9fad1401b5e4e89
https://doi.org/10.1200/jco.2012.30.15_suppl.e17550

Zobrazit plný text záznamu

Limited-stage small cell lung cancer treated with concurrent irinotecan-platinum and radiation therapy

Autor: Teresa Parent, M. E. Picton, Zenith Nelson, Paul R. Walker, Susan Eubanks

Publikováno v: Journal of Clinical Oncology. 29:e17521-e17521

e17521 Background: Concurrent chemoradiation therapy (CRT) is a curative option for limited-stage small cell lung cancer (SCLC). The standard of care in the United States is concurrent etoposide-pl...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a7d15ae50c09f8933aa092b6aa1d527
https://doi.org/10.1200/jco.2011.29.15_suppl.e17521

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání